The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein]
Apomorphine results in increased secretion of and results in increased activity of AMY1A protein; Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Metoclopramide inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]
Apomorphine results in increased expression of AVP protein Metoclopramide inhibits the reaction [Apomorphine results in increased expression of AVP protein]
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]
Apomorphine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Apomorphine results in increased activity of DRD1 protein] [[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]
[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole; Raclopride inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole]; SCH 23390 inhibits the reaction [[[Apomorphine binds to and results in increased activity of DRD1 protein] co-treated with [Apomorphine binds to and results in increased activity of DRD2 protein]] results in decreased susceptibility to Pentylenetetrazole] Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein] DRD2 protein affects the susceptibility to Apomorphine DRD2 protein results in increased susceptibility to Apomorphine
Apomorphine inhibits the reaction [BMP6 protein results in increased expression of HAMP mRNA]; Apomorphine inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; Apomorphine inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] Apomorphine results in decreased secretion of HAMP protein modified form Apomorphine results in decreased expression of HAMP mRNA
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[8-Hydroxy-2-(di-n-propylamino)tetralin binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]
HTR6 protein results in increased susceptibility to Apomorphine Ro4368554 inhibits the reaction [HTR6 protein results in increased susceptibility to Apomorphine]
Bromocriptine results in increased expression of ABCB1 protein Clozapine inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]; Spiperone inhibits the reaction [Bromocriptine results in increased expression of ABCB1 protein]
Bromocriptine results in increased activity of ABCB1B promoter Bromocriptine results in increased expression of ABCB1B mRNA Clozapine inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; eticlopride inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Pertussis Toxin inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]; Spiperone inhibits the reaction [Bromocriptine results in increased activity of ABCB1B promoter]
Bromocriptine results in increased expression of AKR1C3 mRNA methyl cellosolve inhibits the reaction [Bromocriptine results in increased expression of AKR1C3 mRNA]
Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of CYP11A1 mRNA] Bromocriptine results in decreased expression of CYP11A1 protein
Bromocriptine binds to CYP3A4 protein CYP3A4 protein affects the metabolism of Bromocriptine Bromocriptine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]
Bromocriptine affects the expression of DRD2 mRNA DRD2 protein affects the susceptibility to Bromocriptine Bromocriptine binds to and results in increased activity of DRD2 mRNA; Bromocriptine promotes the reaction [Clozapine results in decreased expression of DRD2 mRNA] Bromocriptine results in decreased expression of DRD2 mRNA [Clozapine co-treated with Bromocriptine] results in decreased expression of DRD2 mRNA Bromocriptine results in increased expression of DRD2 mRNA DRD2 polymorphism results in increased susceptibility to Bromocriptine
[1-Methyl-4-phenylpyridinium co-treated with Bromocriptine] results in decreased expression of DRD3 mRNA Bromocriptine results in decreased expression of DRD3 mRNA
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Bromocriptine binds to and results in decreased activity of HTR7 protein
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PCNA protein]
Bromocriptine results in decreased expression of POMC protein alternative form Bromocriptine results in increased expression of POMC mRNA; Bromocriptine results in increased expression of POMC protein modified form Bromocriptine inhibits the reaction [POMC protein results in decreased secretion of Corticosterone]
Bromocriptine promotes the reaction [Estrogens results in increased expression of and results in increased cleavage of PRKCD protein] Bromocriptine affects the localization of PRKCD protein
Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Nalorphine results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] Bromocriptine results in decreased secretion of PRL protein Bromocriptine results in decreased expression of PRL protein Bromocriptine inhibits the reaction [Amisulpride results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased secretion of PRL protein]; Bromocriptine inhibits the reaction [Estradiol results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [methyl cellosolve results in increased expression of PRL protein]; Bromocriptine inhibits the reaction [Olanzapine results in increased expression of PRL protein]; Estradiol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Ethanol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Haloperidol inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [Bromocriptine results in decreased secretion of PRL protein]
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of NOS2 protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein]
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of TGFB1 protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of TGFB1 protein]
Bromocriptine inhibits the reaction [[SOD1 protein mutant form co-treated with Lipopolysaccharides] results in increased secretion of TNF protein]; Bromocriptine inhibits the reaction [SOD1 mutant form results in increased expression of TNF protein] Bromocriptine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
[Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VEGFA protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in decreased expression of VEGFA protein]
Bromocriptine inhibits the reaction [VIP protein results in increased expression of PRL protein] [Bromocriptine co-treated with vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-] inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP mRNA]; Bromocriptine inhibits the reaction [Diethylstilbestrol results in increased expression of VIP protein]
cabergoline results in decreased expression of PRL protein Haloperidol inhibits the reaction [cabergoline results in decreased secretion of PRL protein]; Sulpiride inhibits the reaction [cabergoline results in decreased secretion of PRL protein]
Dihydroergotamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Dihydroergotamine results in decreased activity of CYP1A1 protein Dihydroergotamine results in increased activity of CYP1A1 protein
Fenoldopam results in increased activity of TAAR1 protein [Fenoldopam results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
Lisuride binds to and results in decreased activity of ADRA1A protein; Lisuride promotes the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein]
[Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Lisuride binds to and results in decreased activity of HTR7 protein
Lisuride inhibits the reaction [Metoclopramide results in increased secretion of PRL protein]; Lisuride results in decreased expression of and results in decreased secretion of PRL protein Lisuride analog results in decreased secretion of PRL protein; Lisuride results in decreased secretion of PRL protein
2-aminoindan analog inhibits the reaction [Lysergic Acid Diethylamide binds to HTR2B protein]; Lysergic Acid Diethylamide analog binds to and results in increased activity of HTR2B protein; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Lysergic Acid Diethylamide binds to HTR2B protein]
mesulergine binds to HTR2C protein N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [mesulergine binds to HTR2C protein] Carbamazepine inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Carbamazepine inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]]; Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]; Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]; Plant Extracts inhibits the reaction [Pilocarpine affects the reaction [mesulergine binds to HTR2C protein]]; Plant Extracts inhibits the reaction [Pilocarpine inhibits the reaction [mesulergine binds to HTR2C protein]]
mesulergine binds to HTR7 protein [mesulergine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]
[Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Metergoline binds to and results in decreased activity of HTR7 protein
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]]; SCH 23390 inhibits the reaction [SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]]; SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]]; SCH 23390 inhibits the reaction [SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]]; SK&F 83959 promotes the reaction [CAMK2A protein binds to DRD3 protein]
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein] Pergolide inhibits the reaction [Levodopa results in increased expression of BAX protein]
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein]
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein]
Pergolide inhibits the reaction [Hydrogen Peroxide affects the localization of NFKB1 protein]; Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of NFKB1 protein]
Pergolide inhibits the reaction [Hydrogen Peroxide affects the localization of RELA protein]; Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of RELA protein]
Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of BAX protein]; Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of CDKN1A protein]; Pergolide inhibits the reaction [[Hydrogen Peroxide results in increased expression of TP53 protein] which results in increased expression of MSH2 protein]; Pergolide inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] Pergolide inhibits the reaction [Levodopa results in increased expression of TRP53 protein]
Quinpirole results in increased expression of ABCB1 protein Clozapine inhibits the reaction [Quinpirole results in increased expression of ABCB1 protein]; Spiperone inhibits the reaction [Quinpirole results in increased expression of ABCB1 protein]
Clozapine inhibits the reaction [Quinpirole results in increased activity of ABCB1B promoter]; eticlopride inhibits the reaction [Quinpirole results in increased activity of ABCB1B promoter]; Spiperone inhibits the reaction [Quinpirole results in increased activity of ABCB1B promoter] Quinpirole results in increased expression of ABCB1B mRNA
ADCY5 protein results in increased susceptibility to [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with Quinpirole]; ADCY5 protein results in increased susceptibility to [Colforsin co-treated with Quinpirole]; ADCY5 protein results in increased susceptibility to [dihydrexidine co-treated with Quinpirole]; ADCY5 protein results in increased susceptibility to [Quinpirole co-treated with VIP protein]
[Quinpirole binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium; [Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Quinpirole co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein; DRD2 protein promotes the reaction [Quinpirole results in decreased expression of POU5F1 mRNA]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; JB-788 inhibits the reaction [Quinpirole binds to and results in increased activity of DRD2 protein]; Quinpirole binds to and results in increased activity of DRD2 protein; Sulpiride inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium] Quinpirole results in increased activity of DRD2 protein DRD2 protein results in increased susceptibility to Quinpirole [Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine; cypermethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; decamethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; DRD2 protein affects the reaction [Quinpirole results in decreased transport of Barium]; estradiol 3-benzoate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Mirtazapine inhibits the reaction [Quinpirole binds to DRD2 protein]; Nifedipine inhibits the reaction [DRD2 protein affects the reaction [Quinpirole results in decreased transport of Barium]]; Quinpirole binds to and results in increased activity of DRD2 protein; tautomycin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine] DRD2 protein affects the susceptibility to Quinpirole DRD2 results in increased susceptibility to Quinpirole DRD2 affects the susceptibility to [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Quinpirole]; DRD2 protein affects the reaction [Quinpirole results in increased phosphorylation of CFL1 protein]
Quinpirole results in decreased expression of FOS mRNA; Quinpirole results in decreased expression of FOS protein 8-(3-chlorostyryl)caffeine promotes the reaction [Quinpirole inhibits the reaction [Reserpine results in increased expression of FOS protein]]; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Quinpirole] results in increased expression of FOS protein; [SK&F 81297 co-treated with Quinpirole] results in increased expression of FOS protein; Cocaine promotes the reaction [[SK&F 81297 co-treated with Quinpirole] results in increased expression of FOS protein]; Quinpirole inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS mRNA]; Quinpirole inhibits the reaction [Reserpine results in increased expression of FOS protein]; Quinpirole promotes the reaction [Reserpine results in increased expression of FOS protein]; Reserpine inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Quinpirole] results in increased expression of FOS protein]; Reserpine promotes the reaction [Quinpirole results in increased expression of FOS protein]
[SK&F 81297 co-treated with Quinpirole] results in increased expression of JUNB protein; Cocaine promotes the reaction [[SK&F 81297 co-treated with Quinpirole] results in increased expression of JUNB protein]
Quinpirole results in decreased expression of POU5F1 mRNA DRD2 protein promotes the reaction [Quinpirole results in decreased expression of POU5F1 mRNA]
Quinpirole affects the reaction [Serotonin results in decreased phosphorylation of PPP1R1B protein]; Quinpirole affects the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein]
[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Reserpine co-treated with Quinpirole] results in increased expression of TAC1 mRNA
ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]]
ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]]
ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]]
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of and results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of and results in increased cleavage of CASP3 protein]
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of and results in increased cleavage of CASP7 protein; Acetylcysteine inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of and results in increased cleavage of CASP7 protein]
[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; Calcium promotes the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased phosphorylation of CREB1 protein]; Dizocilpine Maleate inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased phosphorylation of CREB1 protein]; KN 62 inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine inhibits the reaction [Methamphetamine affects the activity of DRD1 protein]; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased susceptibility to ethyl acetate; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased susceptibility to Eugenol; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased abundance of Calcium; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; [SCH 23390 binds to and results in decreased activity of DRD1 protein] inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased susceptibility to ethyl acetate]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; SCH 23390 inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein]; SCH 23390 inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein] [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine binds to and results in increased activity of DRD1 protein] which results in increased susceptibility to Pilocarpine; [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Dizocilpine Maleate] co-treated with [1-hydroxy-3-amino-2-pyrrolidone results in increased activity of DRD1 protein]] results in increased susceptibility to Pilocarpine
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine inhibits the reaction [Methamphetamine affects the activity of DRD2 protein] DRD2 affects the susceptibility to [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Quinpirole]
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of EGR1 mRNA [Scopolamine co-treated with 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine] results in increased expression of EGR1 mRNA
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS mRNA 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine promotes the reaction [Reserpine results in increased expression of FOS protein]; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Quinpirole] results in increased expression of FOS protein; [Pilocarpine co-treated with 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine] results in increased expression of FOS protein; [Scopolamine co-treated with 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine] results in increased expression of FOS mRNA; Quinpirole inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS mRNA]; Reserpine inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Quinpirole] results in increased expression of FOS protein]; Reserpine promotes the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS protein] 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS mRNA; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS protein BP 897 promotes the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOS mRNA]
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOSL1 protein olanzapine inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of FOSL1 protein]
[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased secretion of NGF protein 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased expression of NGF mRNA
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in decreased activity of SLC9A3 protein Buthionine Sulfoximine inhibits the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in decreased activity of SLC9A3 protein]
[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Reserpine co-treated with Quinpirole] results in increased expression of TAC1 mRNA; [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine co-treated with Reserpine] results in increased expression of TAC1 mRNA
browse the term
